BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 30412318)

  • 1. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
    Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
    Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States.
    Young K; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
    J Viral Hepat; 2017 Sep; 24(9):789-796. PubMed ID: 28273387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of obesity and diabetes on waitlist survival, probability of liver transplantation and post-transplant survival among chronic hepatitis C virus patients.
    Aguilar M; Liu B; Holt EW; Bhuket T; Wong RJ
    Liver Int; 2016 Aug; 36(8):1167-75. PubMed ID: 26858016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
    Tanaka T; Voigt MD
    J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age.
    McCabe P; Galoosian A; Wong RJ
    Dig Dis Sci; 2020 May; 65(5):1501-1511. PubMed ID: 31642005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.
    Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation for hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study.
    Khan AS; Adams N; Vachharajani N; Dageforde L; Wellen J; Shenoy S; Crippin JS; Doyle MB; Chapman WC
    Int J Surg; 2020 Mar; 75():84-90. PubMed ID: 32014598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients.
    Sayiner M; Stepanova M; De Avila L; Golabi P; Racila A; Younossi ZM
    Dig Dis Sci; 2020 Feb; 65(2):416-422. PubMed ID: 31451982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Kwong AJ; Kim WR; Flemming JA
    Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.
    Young K; Liu B; Bhuket T; Wong RJ
    J Clin Exp Hepatol; 2020; 10(6):581-589. PubMed ID: 33311895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma.
    Singal AK; Satapathy SK; Reau N; Wong R; Kuo YF
    Dig Liver Dis; 2020 Jan; 52(1):98-101. PubMed ID: 31582326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation.
    Ahn J; Liu B; Bhuket T; Wong RJ
    Dig Dis Sci; 2017 Apr; 62(4):1051-1057. PubMed ID: 28168576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
    Bittermann T; Reddy KR
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2389-2397.e2. PubMed ID: 32971230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
    Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.